A carregar...
Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions
Sipuleucel-T, an autologous cellular immunotherapy manufactured from antigen-presenting cells primed to recognize prostatic acid phosphatase, was the first immunotherapy product approved by the US FDA. It was approved for men with asymptomatic or minimally symptomatic metastatic castration-resistant...
Na minha lista:
| Publicado no: | Future Oncol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Future Medicine Ltd
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5925432/ https://ncbi.nlm.nih.gov/pubmed/29260582 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon-2017-0531 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|